Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/110254
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKollhoff, Lydia-
dc.contributor.authorKipping, Marc-
dc.contributor.authorRauh, Manfred-
dc.contributor.authorCeglarek, Uta-
dc.contributor.authorBarka, Günes-
dc.contributor.authorBarka, Frederik-
dc.contributor.authorSinz, Andrea-
dc.date.accessioned2023-09-07T06:42:45Z-
dc.date.available2023-09-07T06:42:45Z-
dc.date.issued2023-
dc.identifier.urihttps://opendata.uni-halle.de//handle/1981185920/112209-
dc.identifier.urihttp://dx.doi.org/10.25673/110254-
dc.description.abstractWe have developed a rapid and highly specific assay for detecting and monitoring SARS-CoV-2 infections by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). As MALDI-TOF mass spectrometers are available in a clinical setting, our assay has the potential to serve as alternative to the commonly used reverse transcriptase quantitative polymerase chain reaction (RT-qPCR). Sample preparation prior to MALDI-TOF-MS involves the tryptic digestion of SARS-CoV-2 proteins, followed by an enrichment of virus-specific peptides from SARS-CoV-2 nucleoprotein via magnetic antibody beads. Our MALDI-TOF-MS method allows the detection of SARS-CoV-2 nucleoprotein in sample collection medium as low as 8 amol/µl. MALDI-TOF mass spectra are obtained in just a few seconds, which makes our MS-based assay suitable for a high-throughput screening of SARS-CoV-2 in healthcare facilities in addition to PCR. Due to the specific detection of virus peptides, different SARS-CoV-2 variants are readily distinguished from each other. Specifically, we show that our MALDI-TOF-MS assay discriminates SARS-CoV-2 strain B.1.617.2 “delta variant” from all other variants in patients’ samples, making our method highly valuable to monitor the emergence of new virus variants.eng
dc.language.isoeng-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.ddc610-
dc.titleDevelopment of a rapid and specific MALDI-TOF mass spectrometric assay for SARS-CoV-2 detectioneng
dc.typeArticle-
local.versionTypepublishedVersion-
local.bibliographicCitation.journaltitleClinical proteomics-
local.bibliographicCitation.volume20-
local.bibliographicCitation.issue1-
local.bibliographicCitation.publishernameHumana Press-
local.bibliographicCitation.publisherplaceTotowa, NJ-
local.bibliographicCitation.doi10.1186/s12014-023-09415-y-
local.openaccesstrue-
dc.identifier.ppn1853802417-
cbs.publication.displayform2023-
local.bibliographicCitation.year2023-
cbs.sru.importDate2023-09-07T06:42:16Z-
local.bibliographicCitationEnthalten in Clinical proteomics - Totowa, NJ : Humana Press, 2004-
local.accessrights.dnbfree-
Appears in Collections:Open Access Publikationen der MLU

Files in This Item:
File Description SizeFormat 
s12014-023-09415-y.pdf1.3 MBAdobe PDFThumbnail
View/Open